

Zoetis

(ZTS-NYSE)

Stock Rating: Market Perform[↑]
Industry Rating: Market Perform

Upgrading to Market Perform With Cautious Bias

Event

We are upgrading Zoetis stock from Underperform to Market Perform. ZTS shares are down 11.4% since our launch on March 7, 2013 after market close and have underperformed the S&P 500 by ~14%. The stock is close to our \$30 price target, and we see a more balanced risk/reward at current levels.

Impact

Zoetis shares have been under pressure as some competing companies (Virbac, VIRP; and Lilly, LLY) have reported disappointing results. Virbac highlighted “weakness in consumption” for companion animal and livestock products in Europe, while Lilly mentioned “weakness in demand (for food animal products) in many emerging markets consistent with broader industry trends.” The rich valuation of ZTS shares after its successful IPO did not leave a lot of room for such news. Investors are becoming concerned about Zoetis’s 1Q13 performance and more importantly its guidance when it reports for the first time as an independent company on April 30 (8:30 a.m., EDT).

Forecasts

Our 1Q13 EPS forecast and our 2013-2016 EPS forecasts are 10-13% below consensus estimates primarily because we expect a slower rate of margin expansion for Zoetis as an independent company.

Valuation

\$30/share based on DCF, and 23x our 2014 EPS of \$1.40 discounted back.

Recommendation

We are maintaining our cautious bias and would be sellers going into earnings. We also expect a significant increase in supply of shares in 4Q13/1Q14 as Pfizer (PFE) is likely to do a share exchange for the remaining ~80% of ZTS shares. But, given the positive bias on the Street, if Zoetis provides guidance in line with consensus, the shares could rebound.

April 25, 2013

Pharmaceuticals


Alex Arfaei

BMO Nesbitt Burns Inc.
 212-885-4033 / 416-359-4505
 alex.arfaei@bmo.com

Securities Info

Price (24-Apr)	\$30.62	Target Price	\$30
52-Wk High/Low	\$35/\$30	Dividend	\$0.26
Mkt Cap (mm)	\$15,310	Yield	0.8%
Shs O/S (mm, BASIC)	500.0	Float O/S (mm)	99.0
Options O/S (mm)	na	ADVol (30-day, 000s)	1,907

Price Performance



Valuation/Financial Data

(FY-Dec.)	2011A	2012A	2013E	2014E
EPS Pro Forma	\$1.01	\$1.08	\$1.25	\$1.40
P/E			24.5x	21.9x
First Call Cons.			\$1.38	\$1.60
EPS GAAP	\$0.49	\$0.87	\$1.02	\$1.25
FCF	\$0.72	\$0.66	\$1.00	\$1.21
P/FCF			30.6x	25.3x
EBITDA (\$mm)	\$943	\$1,142	\$1,228	\$1,355
EV/EBITDA			15.2x	13.8x
Rev. (\$mm)	\$4,233	\$4,336	\$4,551	\$4,810
EV/Rev			4.1x	3.9x
Quarterly EPS	1Q	2Q	3Q	4Q
2012A	\$0.30	\$0.35	\$0.31	\$0.11
2013E	\$0.30	\$0.37	\$0.33	\$0.24

Balance Sheet Data (30-Sep)

Net Debt (\$mm)	\$3,333	Total Debt/EBITDA	3.0x
Total Debt (\$mm)	\$3,650	EBITDA/IntExp	11.4x
Net Debt/Cap.	71.3%	Price/Book	na

Notes: All values in US\$.

Source: BMO Capital Markets estimates, Bloomberg, Thomson Reuters, and IHS Global Insight.

Exhibit 1. Our 1Q13 Preview: We're More Cautious About Immediate Margin Expansion After Separation From Pfizer


	Q1'13			Q1'12	Y/Y Change (BMO)	Comments:
	Consensus	BMO	BMO vs. Cons.			
Revenues	\$1,078	\$1,093	1%	\$1,047	4%	We include 1% Fx headwind
Gross Profit	\$691	\$690	0%	\$659	5%	We are more cautious about margin expansion
Gross Margin	64.1%	63.1%	-1%	62.9%	0%	
SG&A		\$341		\$331	3%	
Research & Development		\$108		\$93	16%	
Operating Profit	\$259	\$241	-7%	\$235	3%	
Operating Margin	24%	22%	2%	22%		We are more cautious about margin expansion
Taxes	\$67	\$64	-4%	\$76	-15%	
Effective Tax Rate	28.4%	29.0%	1%	33.2%	-4%	We expect lower operating margins and slightly higher tax rate vs. the Street.
Net Income	\$168	\$157	-7%	\$152	3%	
EPS	\$0.33	\$0.30	-10%	\$0.30	-2%	

Sources: Bloomberg Finance LP, Thomson One, BMO Capital Markets Estimates


Exhibit 2. We Continue to See Downside Risk to Consensus Estimates, Specifically for Operating Margins, but if Zoetis Provides Long-Term Guidance in Line With Consensus, Then the Market Will Probably Give it the Benefit of the Doubt

Non-GAAP Measures	FY2013E		FY2014E		FY2015E		FY2016E	
	Street	BMO	Street	BMO	Street	BMO	Street	BMO
Revenue	\$4,533	\$4,551	\$4,806	\$4,810	\$5,080	\$5,057	\$5,344	\$5,295
Gross Margin	64.6%	64.5%	65.3%	64.7%	65.6%	64.9%	65.8%	65.1%
Operating Profit (EBIT)	\$1,104	\$1,034	\$1,259	\$1,157	\$1,397	\$1,275	\$1,513	\$1,400
Operating Margin	24%	23%	26%	24%	28%	25%	28%	26%
Pre-tax Profit	992	928	1,148	1,039	1,287	1,157	1,407	1,285
Effective Tax Rate	30%	29%	30%	29%	29%	29%	29%	29%
Net Income	\$692	\$655	\$806	\$734	\$914	\$817	\$1,003	\$909
Net Margin	15%	14%	17%	15%	18%	16%	19%	17%
EPS	\$1.38	\$1.25	\$1.60	\$1.40	\$1.80	\$1.56	\$1.97	\$1.73
Free Cash Flow per Share	\$1.23	\$1.00	\$1.45	\$1.21	NA	\$1.36	NA	\$1.56
Dividend per share	\$0.27	\$0.26	\$0.32	\$0.33	\$0.37	\$0.39	\$0.54	\$0.47
Dividend Payout Ratio	20%	21%	20%	23%	21%	25%	27%	27%


Source: Zoetis, Thomson One, BMO Capital Markets Pharmaceuticals Research

Exhibit 3. Our Zoetis Revenue Forecast by Species: Ten-Year CAGR of 4.6%

Source: Zoetis, BMO Capital Markets

Exhibit 4. Our Zoetis Revenue Forecast by Geographic Segment: Ten-Year CAGR of 4.5%
(NOTE: Our model uses the average of our revenue forecast by species and geographic segment.)

Source: Zoetis, BMO Capital Markets

Exhibit 5. We Expect Zoetis's Margins to Improve Over Time, Driven Primarily by Improved Operational Efficiency

Source: Zoetis, BMO Capital Markets

Investment Thesis

Zoetis, a former business unit of Pfizer (PFE), is the largest global animal medicines and vaccines company and the only pure-play large-cap animal health company that is publicly traded. Although, we recognize that Zoetis is a unique healthcare growth story with therapeutic and geographically diversified revenues and strong fundamental growth drivers (i.e., growing global demand for animal protein and pet ownership, particularly in emerging markets), we had argued that the stock was overvalued following its IPO (high of \$34.64 on March 14, 2013).

Zoetis's base revenue (excluding acquisitions, divestitures, and Fx) is growing at a similar rate as the animal vaccines and medicines market at roughly 5%, which isn't surprising given that the company has about 19% market share. The market is projected to grow by a CAGR of 6% between 2011 and 2016 (ex-Fx). Forecasting revenues using two different methods (i.e., by species and operating segment), we estimate that Zoetis's revenues should grow by a CAGR of 4.5% through 2023. Moreover, we forecast non-GAAP EPS CAGR of roughly 10% and operating cash flow CAGR of 11% through 2023.

Valuation

We value ZTS shares at \$30 per share using DCF per above forecasts. We assume a 2.5% terminal growth rate, given the sustainability of the business, and as such, our terminal value accounts for nearly 60% of the firm value. On a relative basis, applying a 22-24x multiple,

which is on the top range of that seen with other roughly similar companies, to our 2013E to 2016E non-GAAP EPS estimates produces an average valuation of \$30, in line with our DCF valuation.

Exhibit 6. Our Valuation of ZTS Shares Is Based on DCF and P/E Multiple

FCFF Valuation, \$MM		2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	>2023E
Cash flow from operations		654	769	846	945	1,048	1,154	1,278	1,420	1,568	1,703	1,867	1,914
Y/Y Growth			18%	10%	12%	11%	10%	11%	11%	10%	9%	10%	2.5%
CAPEX		(131)	(132)	(130)	(126)	(132)	(135)	(137)	(135)	(136)	(142)	(136)	(139)
Interest Expense (1-t)		76	83	83	80	80	70	70	70	70	70	41	41
Free Cash Flow to the Firm (FCFF)		600	720	799	899	996	1,090	1,210	1,354	1,502	1,631	1,772	1,816
Discount Period		0.75	1.75	2.75	3.75	4.75	5.75	6.75	7.75	8.75	9.75	10.75	11.75
Discount Rate	8.5%												
Discounted FCFF		564	624	638	662	676	682	698	720	736	736	737	
PV of FCFE (2013-2023)	Total, \$MM	Terminal growth rate: 2.5% Accounts for nearly 60% of firm value given sustainability of business. Source: Zoetis Form 10-K Current outstanding debt Source: Zoetis Form 10-K BMO estimate as of 1Q13.											
Terminal Value at 2023	7,473												
PV of Terminal Value	30,266												
Cash & Equivalents	11,605												
Total Debt	317												
Total Equity Value	3,650												
Minority Interest	15,745												
Total Zoetis Stockholders' Equity Value	(15)												
Diluted shares, MM	15,730												
Equity value per current PFE share	525												
	\$30												

PE Multiple Valuation Using Non-GAAP EPS

		2012A	2013E	2014E	2015E	2016E	2013-16 EPS CAGR
EPS		\$1.08	\$1.25	\$1.40	\$1.56	\$1.73	
PEx	20	\$22	\$25	\$26	\$26	\$27	11.6%
	21	\$23	\$26	\$27	\$28	\$28	
	22	\$24	\$27	\$28	\$29	\$30	
	23	\$25	\$29	\$30	\$30	\$31	
	24	\$26	\$30	\$31	\$32	\$33	
Discount Period		0 1 2 3					
Discount rate		8.5%					
Average		\$30					

Sources: Pfizer Reports, Zoetis Form S-1, BMO Capital Markets Pharmaceuticals Research

Zoetis Income Statement: Our Non-GAAP Quarterly Forecasts

Non-GAAP Income Statement, \$MM	2012A				2013E				2014E			
	Q1 2012	Q2 2012	Q3 2012	Q4 2012	Q1 2013	Q2 2013	Q3 2013	Q4 2013	Q1 2014	Q2 2014	Q3 2014	Q4 2014
Revenues	1,047	1,094	1,019	1,176	1,093	1,151	1,073	1,234	1,151	1,215	1,136	1,307
Cost of Sales	388	382	352	427	403	399	369	446	422	419	388	469
Gross Profit	659	712	667	749	690	751	705	789	729	796	748	838
Selling, Informational and Administrative Expenses	331	351	330	440	341	348	338	459	350	357	347	471
R&D Expenses	93	91	94	121	108	98	91	118	111	101	94	123
Operating Profit	235	270	243	188	241	306	275	211	269	338	307	244
Amortization of Intangible Assets	4	3	4	4	6	6	6	6	7	7	7	7
EBIT	231	267	239	184	236	300	270	206	262	332	300	237
Other (Income) / Deductions -- Net	2	2	(4)	10	14	23	23	23	23	23	23	23
Income From Cont. Operations Before Provision for Taxes	229	265	243	174	222	277	247	182	239	309	277	214
(Benefit) / Provision for Taxes on Income	76	90	89	117	64	80	72	53	69	90	80	62
Net income/(loss) before allocation to non-controlling interests	153	175	154	57	158	197	175	129	170	219	197	152
Less: Income / (Loss) Attributable to Non-Controlling Interests	1	(1)		0	1	1	1	1	1	1	1	1
Net Income/ (loss) Attributable to Zoetis	152	176	154	57	157	196	174	128	169	218	196	151
Earnings Per Share - Basic	\$0.30	\$0.35	\$0.31	\$0.11	\$0.31	\$0.39	\$0.35	\$0.26	\$0.34	\$0.44	\$0.39	\$0.30
Earnings Per Share - Diluted	\$0.30	\$0.35	\$0.31	\$0.11	\$0.30	\$0.37	\$0.33	\$0.24	\$0.32	\$0.42	\$0.37	\$0.29
Weighted-Average Shares - Basic	500	500	500	500	500	500	500	500	500	500	500	500
Weighted-Average Shares - Diluted	500	500	500	500	525	525	525	525	525	525	525	525
Dividend per Share	\$0.00	\$0.00	\$0.00	\$0.00	\$0.07	\$0.07	\$0.07	\$0.07	\$0.08	\$0.08	\$0.08	\$0.08

	2012E				2013E				2014E			
	Q1 2012	Q2 2012	Q3 2012	Q4 2012	Q1 2013	Q2 2013	Q3 2013	Q4 2013	Q1 2014	Q2 2014	Q3 2014	Q4 2014
Growth Rates												
Revenue growth (YOY)	7%	2%	-3%	4%	4%	5%	5%	5%	5%	6%	6%	6%
Gross Profit	7%	10%	1%	2%	5%	6%	6%	5%	6%	6%	6%	6%
Operating Income (EBIT)	31%	46%	5%	-6%	2%	13%	13%	12%	11%	11%	11%	16%
Net Income	26%	54%	5%	-54%	3%	11%	13%	125%	8%	11%	12%	18%
EPS- Diluted	26%	54%	5%	-63%	-15%	21%	8%	115%	8%	11%	12%	18%
Dividend									25%	25%	25%	25%
Margins												
Gross Profit	63%	65%	65%	64%	63%	65%	66%	64%	63%	65%	66%	64%
Operating Profit	22%	25%	24%	16%	22%	27%	26%	17%	23%	28%	27%	19%
Net Income	15%	16%	15%	5%	14%	17%	16%	10%	15%	18%	17%	12%
Return Analysis												
Payout Ratio					22%	17%	20%	27%	25%	20%	22%	28%

Sources: Pfizer Reports, Zoetis Form S-1, BMO Capital Markets Pharmaceuticals Research

Zoetis Income Statement: Our Non-GAAP Annual Forecasts

Non-GAAP Income Statement, \$MM	2010A	2011A	2012A	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
Revenues	\$3,582	\$4,233	\$4,336	\$4,551	\$4,810	\$5,057	\$5,295	\$5,533	\$5,775	\$6,026	\$6,287	\$6,549	\$6,819	\$7,092
Cost of Sales	1,318	1,581	1,549	1,617	1,699	1,776	1,849	1,921	1,994	2,068	2,145	2,221	2,299	2,377
Gross Profit	2,264	2,652	2,787	2,935	3,111	3,281	3,446	3,612	3,782	3,958	4,142	4,327	4,520	4,715
SG&A	1,365	1,443	1,452	1,487	1,525	1,561	1,590	1,619	1,647	1,676	1,706	1,734	1,763	1,791
R&D	411	407	399	414	428	445	456	466	475	485	493	508	523	537
Operating Profit	488	802	936	1,034	1,157	1,275	1,400	1,527	1,659	1,797	1,943	2,085	2,234	2,387
Amortization of Intangible Assets	17	20	15	22	26	26	26	26	26	26	26	26	26	26
Restructuring Charges & Certain Acquisition-Related Costs	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other (Income) / Deductions -- Net	12	12	10	84	93	93	88	88	75	74	74	74	74	34
Income From Cont. Operations Before Provision for Taxes	459	770	911	928	1,039	1,157	1,285	1,413	1,558	1,697	1,843	1,985	2,135	2,327
(Benefit) / Provision for Taxes on Income	183	264	372	269	301	335	373	410	452	492	534	576	619	675
Effective Tax Rate	39.9%	34.3%	40.8%	29.0%	29.0%	29.0%	29.0%	29.0%	29.0%	29.0%	29.0%	29.0%	29.0%	29.0%
Net income/(loss) before allocation to non-controlling interests	276	506	539	659	738	821	913	1,003	1,106	1,205	1,309	1,410	1,516	1,652
Gain / (Loss) Attributable to Non-Controlling Interests	1	3	0	4	4	4	4	4	4	4	4	4	4	4
Net Income (Loss) Attributable to Zoetis	\$275	\$503	\$539	\$655	\$734	\$817	\$909	\$999	\$1,102	\$1,201	\$1,305	\$1,406	\$1,512	\$1,648
Earnings Per Share - Basic	\$0.55	\$1.01	\$1.08	\$1.31	\$1.47	\$1.64	\$1.82	\$2.00	\$2.22	\$2.42	\$2.64	\$2.86	\$3.09	\$3.40
Earnings Per Share - Diluted	\$0.55	\$1.01	\$1.08	\$1.25	\$1.40	\$1.56	\$1.73	\$1.91	\$2.11	\$2.31	\$2.51	\$2.72	\$2.94	\$3.23
Weighted-Average Shares - Basic	500	500	500	500	500	500	499	499	497	496	494	491	489	485
Weighted-Average Shares - Diluted	500	500	500	525	525	525	524	524	522	521	519	516	514	510
Cash Dividend Paid per Share				\$0.26	\$0.33	\$0.39	\$0.47	\$0.54	\$0.62	\$0.68	\$0.68	\$0.71	\$0.75	\$0.75

	2010A	2011A	2012A	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
Growth Rates														
Revenue	30%	18%	2%	5%	6%	5%	5%	5%	4%	4%	4%	4%	4%	4%
Gross Profit	29%	17%	5%	5%	6%	5%	5%	5%	5%	5%	5%	4%	4%	4%
Operating Profit	49%	64%	17%	10%	12%	10%	10%	9%	9%	8%	8%	7%	7%	7%
Net Income	54%	83%	7%	22%	12%	11%	11%	10%	10%	9%	9%	8%	8%	9%
EPS		83%	7%	16%	12%	11%	11%	10%	11%	9%	9%	8%	8%	10%
Dividend per share					25%	20%	20%	15%	15%	10%	0%	5%	5%	0%
Margins														
Gross Profit	63.2%	62.7%	64.3%	64.5%	64.7%	64.9%	65.1%	65.3%	65.5%	65.7%	65.9%	66.1%	66.3%	66.5%
Operating Profit	14%	19%	22%	23%	24%	25%	26%	28%	29%	30%	31%	32%	33%	34%
Net Income	7.7%	11.9%	12.4%	14.4%	15.3%	16.2%	17.2%	18.1%	19.1%	19.9%	20.8%	21.5%	22.2%	23.2%
Return Analysis														
Payout Ratio				21%	23%	25%	27%	28%	29%	30%	27%	26%	26%	23%

Sources: Pfizer Reports, Zoetis Form S-1, BMO Capital Markets Pharmaceuticals Research

Zoetis Income Statement: Our GAAP Annual Forecasts

GAAP Income Statement, \$MM	2010A	2011A	2012A	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
Revenues	\$3,582	\$4,233	\$4,336	\$4,551	\$4,810	\$5,057	\$5,295	\$5,533	\$5,775	\$6,026	\$6,287	\$6,549	\$6,819	\$7,092
Cost of Sales	1,444	1,652	1,563	1,621	1,703	1,780	1,853	1,925	1,998	2,072	2,149	2,225	2,303	2,381
Gross Profit	2,138	2,581	2,773	2,931	3,107	3,277	3,442	3,608	3,778	3,954	4,138	4,323	4,516	4,711
SG&A	1,382	1,453	1,470	1,507	1,541	1,573	1,602	1,631	1,659	1,688	1,718	1,746	1,775	1,803
R&D Expenses	411	427	409	434	444	457	468	478	487	497	505	520	535	549
Amortization of Intangible Assets	58	69	64	66	66	66	66	66	66	66	66	66	66	66
Restructuring Charges & Certain Acquisition-Related Costs	202	154	135	84	32	24	24	24	24	24	24	24	24	24
Other (Income) / Deductions -- Net	(93)	84	(15)	84	93	93	88	88	75	74	74	74	74	34
Income Before Provision for Taxes	178	394	710	756	931	1,065	1,193	1,321	1,466	1,605	1,751	1,893	2,043	2,235
(Benefit) / Provision for Taxes on Income	67	146	274	219	270	309	346	383	425	466	508	549	592	648
Net income/(loss) before allocation to non-controlling interests	111	248	436	537	661	756	847	938	1,041	1,140	1,243	1,344	1,450	1,587
Gain / (Loss) Attributable to Non-Controlling Interests	1	3	0	4	4	4	4	4	4	4	4	4	4	4
Net Income (Loss) Attributable to Zoetis	\$110	\$245	\$436	\$533	\$657	\$752	\$843	\$934	\$1,037	\$1,136	\$1,239	\$1,340	\$1,446	\$1,583
Earnings Per Share - Basic	\$0.22	\$0.49	\$0.87	\$1.07	\$1.31	\$1.50	\$1.69	\$1.87	\$2.08	\$2.29	\$2.51	\$2.73	\$2.96	\$3.26
Earnings Per Share - Diluted	\$0.22	\$0.49	\$0.87	\$1.02	\$1.25	\$1.43	\$1.61	\$1.78	\$1.98	\$2.18	\$2.39	\$2.60	\$2.82	\$3.10
Weighted-Average Shares - Basic	500	500	500	500	500	500	499	499	497	496	494	491	489	485
Weighted-Average Shares - Diluted	500	500	500	525	525	525	524	524	522	521	519	516	514	510
Cash Dividend per Share	\$0.00	\$0.00	\$0.00	\$0.26	\$0.33	\$0.39	\$0.47	\$0.54	\$0.62	\$0.68	\$0.68	\$0.71	\$0.75	\$0.75

Note: Includes revenues and expenses from acquisitions from the acquisition date

Sources: Pfizer Reports, Zoetis Form S-1, BMO Capital Markets Pharmaceuticals Research

Zoetis Balance Sheet

Zoetis Balance Sheet, \$MM	2010A	2011A	2012A	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
Assets														
Cash and cash equivalents	63	79	317	710	1,174	1,665	1,783	2,291	2,070	2,603	3,188	3,845	4,504	3,889
Accounts receivable, less allowance for doubtful accounts	773	871	900	912	995	1,101	1,198	1,268	1,356	1,432	1,475	1,478	1,459	1,454
Inventories	995	1,063	1,345	1,262	1,278	1,304	1,329	1,391	1,443	1,484	1,538	1,593	1,648	1,668
Current deferred tax assets	97	96	101	91	90	89	89	89	89	89	89	89	89	89
Other current assets	188	202	201	215	217	218	218	218	218	218	218	218	218	218
Total current assets	2,116	2,311	2,864	3,192	3,754	4,376	4,617	5,257	5,176	5,826	6,508	7,222	7,918	7,318
Property, plant and equipment, less accumulated depreciation	1,148	1,243	1,241	1,246	1,244	1,233	1,219	1,205	1,187	1,164	1,131	1,093	1,053	1,001
Identifiable intangible assets, less accumulated amortization	924	928	868	802	736	670	604	538	472	406	340	274	208	142
Goodwill	934	989	985	985	985	985	985	985	985	985	985	985	985	985
Non-current deferred tax assets	70	143	216	201	200	200	200	200	200	200	200	200	200	200
Other noncurrent assets	92	97	88	83	83	82	82	82	82	82	82	82	82	82
Total Assets	5,284	5,711	6,262	6,509	7,002	7,546	7,708	8,268	8,102	8,663	9,247	9,857	10,446	9,728
Liabilities and Equity														
Current portion of allocated long-term debt	0	0	73	0	0	0	0	0	0	0	0	0	0	0
Current portion of long-term debt	38	0	0	0	0	400	0	750	0	0	0	0	1,350	0
Accounts payable	206	214	319	243	230	213	194	190	191	185	192	199	206	213
Income taxes payable	24	18	30	31	32	32	32	32	32	32	32	32	32	32
Accrued compensation and related items	144	150	194	176	181	184	188	191	195	198	202	206	209	213
Other current liabilities	396	461	507	444	433	432	431	431	431	431	431	431	431	431
Total current liabilities	808	843	1,123	894	876	1,261	845	1,595	849	847	858	868	2,229	890
Allocated long-term debt	673	575	509	0	0	0	0	0	0	0	0	0	0	0
Long-term debt	0	0	0	3,650	3,650	3,250	3,250	2,500	2,500	2,500	2,500	2,500	1,150	1,150
Noncurrent deferred tax liabilities	218	311	323	317	316	316	316	316	316	316	316	316	316	316
Other taxes payable	100	122	159	134	129	129	129	129	129	129	129	129	129	129
Other noncurrent liabilities	141	124	107	104	103	103	103	103	103	103	103	103	103	103
Total Liabilities	1,940	1,975	2,221	5,099	5,074	5,058	4,642	4,642	3,896	3,894	3,905	3,915	3,926	2,587
Commitments and Contingencies														
Total Equity	3,344	3,736	4,041	1,410	1,927	2,488	3,065	3,626	4,205	4,769	5,342	5,941	6,520	7,141
Total liabilities and equity	5,284	5,711	6,262	6,509	7,002	7,546	7,708	8,268	8,102	8,663	9,247	9,857	10,446	9,728

Sources: Pfizer Reports, Zoetis Form S-1, BMO Capital Markets Pharmaceuticals Research

Zoetis Statement of Cash Flows

Zoetis Statement of Cash Flows, \$MM	2010A	2011A	2012A	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
Operating activities														
GAAP Net income/(loss) before allocation to non-controlling interests	111	248	436	537	661	756	847	938	1,041	1,140	1,243	1,344	1,450	1,587
Adjustments:														
Depreciation and amortization expense	185	205	200	192	200	207	206	212	219	226	233	240	248	255
Share-based compensation expense	16	19	28	30	30	30	30	30	30	30	30	30	30	30
Asset write-offs and impairments	16	78	10	0	0	0	0	0	0	0	0	0	0	0
Net gains on sales of assets	(101)	(1)	0	0	0	0	0	0	0	0	0	0	0	0
Deferred taxes	(68)	65	(74)	19	2	0	(0)	(0)	(0)	(0)	(0)	(0)	0	0
Other non-cash adjustments	(5)	0	3	0	0	0	0	0	0	0	0	0	0	0
Other changes in assets and liabilities, net of acquisitions and divestitures:	100	(117)	(149)	(123)	(123)	(147)	(138)	(132)	(136)	(119)	(87)	(47)	(25)	(5)
Net cash provided by operating activities	254	497	454	654	769	846	945	1,048	1,154	1,278	1,420	1,568	1,703	1,867
Investing Activities														
Purchases of property, plant and equipment	(124)	(135)	(126)	(131)	(132)	(130)	(126)	(132)	(135)	(137)	(135)	(136)	(142)	(136)
Net proceeds from sales of assets	203	34	3	0	0	0	0	0	0	0	0	0	0	0
Acquisitions, net of cash acquired	(81)	(345)	0	0	0	0	0	0	0	0	0	0	0	0
Other investing activities	(7)	(3)	(12)	0	0	0	0	0	0	0	0	0	0	0
Net cash used in investing activities	(9)	(449)	(135)	(131)	(132)	(130)	(126)	(132)	(135)	(137)	(135)	(136)	(142)	(136)
Financing activities														
Debt - Net issuance / payment	0	(143)	0	2,650	0	0	(400)	0	(750)	0	0	0	0	(1,350)
Cash dividends paid	(207)	(416)	(63)	(130)	(162)	(195)	(234)	(268)	(308)	(338)	(336)	(351)	(367)	(364)
Purchase of subsidiary shares from noncontrolling interests	(3)	0	0	0	0	0	0	0	0	0	0	0	0	0
Share repurchases	0	0	0	0	(11)	(31)	(67)	(140)	(183)	(270)	(364)	(425)	(535)	(632)
Net financing activities with Pfizer	(67)	529	(15)	(2,650)	0	0	0	0	0	0	0	0	0	0
Net cash provided by/(used in) financing activities	(277)	(30)	(78)	(130)	(174)	(226)	(700)	(408)	(1,241)	(607)	(700)	(776)	(902)	(2,346)
Effect of exchange-rate changes on cash and cash equivalents	(4)	(2)	(3)	0	0	0	0	0	0	0	0	0	0	0
Net increase/(decrease) in cash and cash equivalents	(36)	16	238	393	463	491	119	508	(222)	534	585	657	659	(615)
Cash and cash equivalents, as of beginning of year	99	63	79	317	710	1,174	1,665	1,783	2,291	2,070	2,603	3,188	3,845	4,504
Cash and cash equivalents, as of end of year	63	79	317	710	1,174	1,665	1,783	2,291	2,070	2,603	3,188	3,845	4,504	3,889

Sources: Pfizer Reports, Zoetis Form S-1, BMO Capital Markets Pharmaceuticals Research


Other companies mentioned (priced as of the close on April 24, 2013):

Pfizer (PFE, \$30.60, Outperform)

Eli Lilly (LLY, \$56.05, Market Perform)

Virbac (EPA:VIRP, 148.90, Not Rated)

Zoetis Inc. (ZTS)




FYE (Dec.)	EPS US\$	P/E	DPS \$	Yield %	Payout %	BV \$	P/B	ROE %
Current*	1.05	31	0.00	0.0	0	ND	nm	nm

ZTS - Rating as of 1-Feb-13 = NR		
Date	Rating Change	Share Price
1 7-Mar-13	NR to Und.	\$34.56

* Current EPS is the 4 Quarter Trailing to Q4/2012.

Last Price (April 23, 2013): \$32.22
Sources: IHS Global Insight, Thomson Reuters, BMO Capital Markets.

Pfizer Inc. (PFE)



FYE (Dec.)	EPS US\$	P/E Hi - Lo	DPS US\$	Yield% Hi - Lo	Payout %	BV US\$	P/B Hi - Lo	ROE %
1992	0.27	26.9 20.1	0.12	2.3 1.7	46	1.2	6.0 4.5	
1993	0.31	21.5 14.1	0.14	3.2 2.1	45	1.0	6.6 4.4	28
1994	0.35	18.9 12.6	0.16	3.5 2.4	45	1.1	5.8 3.9	33
1995	0.41	27.2 14.9	0.09	1.4 0.8	21	1.4	7.7 4.3	32
1996	0.50	30.4 19.4	0.20	2.1 1.3	40	1.8	8.5 5.4	31
1997	0.53	50.3 25.0	0.23	1.7 0.9	43	2.0	13.1 6.5	28
1998	0.51	84.3 45.5	0.29	1.3 0.7	58	2.3	>15 10.2	24
1999	0.82	61.0 38.5	0.36	1.1 0.7	44	2.3	>15 13.7	36
2000	1.02	48.3 29.4	0.44	1.5 0.9	43	2.6	>15 11.8	42
2001	1.27	37.8 26.8	0.52	1.5 1.1	41	2.9	>15 11.7	47
2002	1.53	28.7 16.4	0.60	2.4 1.4	39	3.2	13.6 7.8	50
2003	1.75	21.1 15.4	0.68	2.5 1.8	39	8.5	4.3 3.2	30
2004	2.12	18.3 10.4	0.76	3.5 2.0	36	9.1	4.3 2.4	24
2005	2.02	14.5 10.0	0.96	4.7 3.3	48	8.9	3.3 2.3	22
2006	2.08	13.8 9.7	1.16	5.7 4.1	56	10.0	2.9 2.0	22
2007	2.20	12.7 10.1	1.28	5.8 4.6	58	9.6	2.9 2.3	22
2008	2.43	10.1 5.9	1.28	9.0 5.2	53	8.5	2.9 1.7	27
2009	2.02	9.4 5.8	0.72	6.2 3.8	36	11.2	1.7 1.0	21
2010	2.22	9.2 6.3	0.80	5.7 3.9	36	11.0	1.9 1.3	20
2011	2.31	9.5 7.1	0.88	5.4 4.0	38	10.8	2.0 1.5	21
2012	2.19	11.9 9.0	0.96	4.9 3.7	44	11.1	2.4 1.8	20
Range*		84.3 5.8		9.0 0.7			>15 1.0	
Current*	2.20	13.1	0.96	3.3	44	11.2	2.6	20
Growth(%):								
5 Year:	0.6		-5.6			3.1		
10 Year:	3.3		4.8			13.2		
20 Year:	10.9		10.1			12.0		

PFE - Rating as of 13-May-10 = Mkt


Date	Rating Change	Share Price
1 2-Feb-11	Mkt to OP	\$18.96
2 3-May-11	OP to NR	\$20.44
3 27-Sep-12	NR to OP	\$24.96

* Current EPS is the 4 Quarter Trailing to Q4/2012.
 * Valuation metrics are based on high and low for the fiscal year.
 * Range indicates the valuation range for the period presented above.

Last Price (April 23, 2013): \$31.08

Sources: IHS Global Insight, Thomson Reuters, BMO Capital Markets.

Eli Lilly & Co. (LLY)



FYE (Dec.)	EPS US\$	P/E Hi - Lo		DPS US\$	Yield% Hi - Lo		Payout %	BV US\$	P/B Hi - Lo		ROE %	LLY - Rating as of 13-May-10 = OP				
1992	1.22	18.0	11.8	0.55	3.8	2.5	45	4.2	5.2	3.5		Date	Rating Change	Share Price		
1993	1.15	14.2	9.5	0.63	5.7	3.8	54	3.9	4.2	2.8	28					
1994	1.10	15.1	10.7	0.65	5.5	3.9	59	4.6	3.6	2.6	26	1	3-May-11	OP to NR	\$38.09	
1995	1.15	24.8	13.2	0.69	4.5	2.4	60	4.9	5.8	3.1	24	2	18-May-12	NR to Mkt	\$40.44	
1996	1.30	30.9	18.8	0.72	3.0	1.8	55	5.5	7.3	4.4	25					
1997	1.60	44.0	21.9	0.80	2.3	1.1	50	4.2	>15	8.4	33					
1998	1.93	47.3	29.9	0.92	1.6	1.0	48	4.0	>15	14.3	47					
1999	2.28	42.9	26.6	1.04	1.7	1.1	46	4.6	>15	13.2	>50					
2000	2.65	41.1	20.4	1.12	2.1	1.0	42	5.4	>15	10.1	>50					
2001	2.76	34.4	25.4	1.24	1.8	1.3	45	6.3	>15	11.1	47					
2002	2.55	33.1	17.2	1.34	3.1	1.6	53	7.4	11.4	5.9	37					
2003	2.58	28.6	20.5	1.42	2.7	1.9	55	8.7	8.5	6.1	32					
2004	2.82	27.3	17.9	1.52	3.0	2.0	54	9.7	8.0	5.2	31					
2005	2.88	21.2	17.2	1.60	3.2	2.6	56	9.6	6.4	5.2	30					
2006	3.18	18.6	15.8	1.70	3.4	2.9	53	9.7	6.1	5.2	33					
2007	3.55	17.2	13.8	1.88	3.8	3.1	53	12.1	5.1	4.1	33					
2008	4.02	14.3	7.1	1.96	6.8	3.4	49	5.9	9.7	4.8	45					
2009	4.43	9.2	6.1	1.96	7.2	4.8	44	8.3	4.9	3.3	>50					
2010	4.74	8.0	6.8	1.96	6.1	5.1	41	10.8	3.5	3.0	50					
2011	4.41	9.5	7.6	1.96	5.9	4.7	44	11.7	3.6	2.9	39					
2012	3.39	15.9	11.0	1.96	5.3	3.6	58	13.8	3.9	2.7	27					
Range*:		47.3	6.1		7.2	1.0			>15	2.6						
Current*	3.39	16.8		1.96	3.5		58	13.8	4.1		24					
Growth(%):																
5 Year:	-1.4			0.8				2.8								
10 Year:	2.8			3.9				6.5								
20 Year:	5.5			6.1				6.2								

* Current EPS is the 4 Quarter Trailing to Q4/2012.

* Valuation metrics are based on high and low for the fiscal year.

* Range indicates the valuation range for the period presented above.

Last Price (April 23, 2013): \$58.33

Sources: IHS Global Insight, Thomson Reuters, BMO Capital Markets.

Important Disclosures

Analyst's Certification

I, Alex Arfaei, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities or issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Analysts who prepared this report are compensated based upon (among other factors) the overall profitability of BMO Capital Markets and their affiliates, which includes the overall profitability of investment banking services. Compensation for research is based on effectiveness in generating new ideas and in communication of ideas to clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

Analysts employed by BMO Nesbitt Burns Inc. and/or BMO Capital Markets Ltd. are not registered as research analysts with FINRA. These analysts may not be associated persons of BMO Capital Markets Corp. and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account.

Company Specific Disclosure

Company Specific Disclosures for ZTS

Methodology and Risks to Our Price Target/Valuation

Methodology: DCF and P/E Multiple

Risks: Demand for animal health products could fluctuate and there are relatively low barriers to entry for competitors.

Company Specific Disclosures for PFE

9 - BMO Capital Markets makes a market in this security.

Methodology and Risks to Our Price Target/Valuation

Methodology: DCF: Free Cash Flow To Equity.

Risks: Uncertainty of Phase 3 Pipeline.

Company Specific Disclosures for LLY

5 - BMO Capital Markets or an affiliate received compensation for products or services other than investment banking services within the past 12 months.

6C - This issuer is a client (or was a client) of BMO Capital Markets or an affiliate within the past 12 months: Non-Securities Related Services

9 - BMO Capital Markets makes a market in this security.

Methodology and Risks to Our Price Target/Valuation

Methodology: DCF: Free Cash Flow To Equity and multiple of sales.

Risks: Uncertainty of Phase 3 Pipeline.

Distribution of Ratings (March 31, 2013)

Rating Category	BMO Rating	BMOCM US Universe*	BMOCM US IB Clients**	BMOCM US IB Clients***	BMOCM Universe****	BMOCM IB Clients*****	Starmine Universe
Buy	Outperform	37.3%	16.5%	53.8%	38.2%	51.3%	53.2%
Hold	Market Perform	58.0%	8.8%	44.6%	56.8%	47.7%	41.1%
Sell	Underperform	4.7%	3.7%	1.5%	4.9%	1.0%	5.7%

* Reflects rating distribution of all companies covered by BMO Capital Markets Corp. equity research analysts.

** Reflects rating distribution of all companies from which BMO Capital Markets Corp. has received compensation for Investment Banking services as percentage within ratings category.

*** Reflects rating distribution of all companies from which BMO Capital Markets Corp. has received compensation for Investment Banking services as percentage of Investment Banking clients.

**** Reflects rating distribution of all companies covered by BMO Capital Markets equity research analysts.

***** Reflects rating distribution of all companies from which BMO Capital Markets has received compensation for Investment Banking services as percentage of Investment Banking clients.

Rating and Sector Key (as of April 5, 2013)

We use the following ratings system definitions:

OP = Outperform - Forecast to outperform the analyst's coverage universe on a total return basis;

Mkt = Market Perform - Forecast to perform roughly in line with the analyst's coverage universe on a total return basis;

Und = Underperform - Forecast to underperform the analyst's coverage universe on a total return basis;

(S) = Speculative investment;

NR = No rating at this time; and

R = Restricted - Dissemination of research is currently restricted.

BMO Capital Markets' seven Top 15 lists guide investors to our best ideas according to different objectives (CDN Large Cap, CDN Small Cap, US Large Cap, US Small Cap, Income, CDN Quant, and US Quant have replaced the Top Pick rating).

Prior BMO Capital Markets Rating System (January 4, 2010 – April 4, 2013):

http://researchglobal.bmocapitalmarkets.com/documents/2013/prior_rating_system.pdf

Other Important Disclosures

For Other Important Disclosures on the stocks discussed in this report, please go to http://researchglobal.bmocapitalmarkets.com/Public/Company_Disclosure_Public.aspx or write to Editorial Department, BMO Capital Markets, 3 Times Square, New York, NY 10036 or Editorial Department, BMO Capital Markets, 1 First Canadian Place, Toronto, Ontario, M5X 1H3.

Dissemination of Research

Our research publications are available via our web site <http://www.bmocm.com/research/>. Institutional clients may also receive our research via FIRST CALL, Thomson Reuters, Bloomberg, FactSet, Capital IQ, and TheMarkets.com. All of our research is made widely available at the same time to all BMO Capital Markets client groups entitled to our research. Additional dissemination may occur via email or regular mail. Please contact your investment advisor or institutional salesperson for more information.

Conflict Statement

A general description of how BMO Financial Group identifies and manages conflicts of interest is contained in our public facing policy for managing conflicts of interest in connection with investment research, which is available at http://researchglobal.bmocapitalmarkets.com/Public/Conflict_Statement_Public.aspx.

General Disclaimer

“BMO Capital Markets” is a trade name used by the BMO Investment Banking Group, which includes the wholesale arm of Bank of Montreal and its subsidiaries BMO Nesbitt Burns Inc., BMO Capital Markets Ltd. in the U.K. and BMO Capital Markets Corp. in the U.S. BMO Nesbitt Burns Inc., BMO Capital Markets Ltd. and BMO Capital Markets Corp are affiliates. Bank of Montreal or its subsidiaries (“BMO Financial Group”) has lending arrangements with, or provide other remunerated services to, many issuers covered by BMO Capital Markets. The opinions, estimates and projections contained in this report are those of BMO Capital Markets as of the date of this report and are subject to change without notice. BMO Capital Markets endeavours to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, BMO Capital Markets makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to BMO Capital Markets or its affiliates that is not reflected in this report. The information in this report is not intended to be used as the primary basis of investment decisions, and because of individual client objectives, should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer to sell or the solicitation of an offer to buy any security. BMO Capital Markets or its affiliates will buy from or sell to customers the securities of issuers mentioned in this report on a principal basis. BMO Capital Markets or its affiliates, officers, directors or employees have a long or short position in many of the securities discussed herein, related securities or in options, futures or other derivative instruments based thereon. The reader should assume that BMO Capital Markets or its affiliates may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein.

Additional Matters

To Canadian Residents: BMO Nesbitt Burns Inc., affiliate of BMO Capital Markets Corp., furnishes this report to Canadian residents and accepts responsibility for the contents herein subject to the terms set out above. Any Canadian person wishing to effect transactions in any of the securities included in this report should do so through BMO Nesbitt Burns Inc.

The following applies if this research was prepared in whole or in part by Andrew Breichmanas, Tony Robson, or Edward Sterck: This research is not prepared subject to Canadian disclosure requirements. This research is prepared by BMO Capital Markets Limited and subject to the regulations of the Financial Conduct Authority (FCA) in the United Kingdom. FCA regulations require that a firm providing research disclose its ownership interest in the issuer that is the subject of the research if it and its affiliates own 5% or more of the equity of the issuer. Canadian regulations require that a firm providing research disclose its ownership interest in the issuer that is the subject of the research if it and its affiliates own 1% or more of the equity of the issuer that is the subject of the research. Therefore BMO Capital Markets Limited will only disclose its and its’ affiliates ownership interest in the subject issuer if such ownership exceeds 5% of the equity of the issuer.

To U.S. Residents: BMO Capital Markets Corp. and/or BMO Nesbitt Burns Securities Ltd., affiliates of BMO NB, furnish this report to U.S. residents and accept responsibility for the contents herein, except to the extent that it refers to securities of Bank of Montreal. Any U.S. person wishing to effect transactions in any security discussed herein should do so through BMO Capital Markets Corp. and/or BMO Nesbitt Burns Securities Ltd.

To U.K. Residents: In the UK this document is published by BMO Capital Markets Limited which is authorised and regulated by the Financial Conduct Authority. The contents hereof are intended solely for the use of, and may only be issued or passed on to, (I) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (II) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together referred to as “relevant persons”). The contents hereof are not intended for the use of and may not be issued or passed on to, retail clients.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

BMO Financial Group (NYSE, TSX: BMO) is an integrated financial services provider offering a range of retail banking, wealth management, and investment and corporate banking products. BMO serves Canadian retail clients through BMO Bank of Montreal and BMO Nesbitt Burns. In the United States, personal and commercial banking clients are served by BMO Harris Bank N.A., Member FDIC. Investment and corporate banking services are provided in Canada and the US through BMO Capital Markets.

BMO Capital Markets is a trade name used by BMO Financial Group for the wholesale banking businesses of Bank of Montreal, BMO Harris Bank N.A., BMO Ireland Plc, and Bank of Montreal (China) Co. Ltd. and the institutional broker dealer businesses of BMO Capital Markets Corp. (Member SIPC), BMO Nesbitt Burns Securities Limited (Member SIPC) and BMO Capital Markets GKST Inc. (Member SIPC) in the U.S., BMO Nesbitt Burns Inc. (Member Canadian Investor Protection Fund) in Canada, Europe and Asia, BMO Capital Markets Limited in Europe, Asia and Australia and BMO Advisors Private Limited in India. "Nesbitt Burns" is a registered trademark of BMO Nesbitt Burns Corporation Limited, used under license. "BMO Capital Markets" is a trademark of Bank of Montreal, used under license. "BMO (M-Bar roundel symbol)" is a registered trademark of Bank of Montreal, used under license.

® Registered trademark of Bank of Montreal in the United States, Canada and elsewhere.
TM Trademark Bank of Montreal

©COPYRIGHT 2013 BMO CAPITAL MARKETS CORP.

A member of BMO  Financial Group